PressSeptember 19, 2022 Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency
PressSeptember 19, 2022 Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder
PressSeptember 19, 2022 PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted
PressSeptember 19, 2022 Core One Labs’ Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
PressSeptember 19, 2022 Braxia Scientific Announces Court Approval of Class Action Settlement in Canada
PressSeptember 19, 2022 Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants
PressSeptember 19, 2022 Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™
PressSeptember 16, 2022 PharmaTher Announces Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine
PressSeptember 16, 2022 Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program
PressSeptember 16, 2022 Innovation1 Biotech Appoints Frederick E. Pierce, II to its Board of Directors
PressSeptember 15, 2022 Blackhawk’s MindBio Therapeutics Announces Reveal Date for Presentation of Phase 1 Clinical Trial Data
PressSeptember 15, 2022 HealingMaps Announces $1 Million in Seed Funding to Power Growth in Psychedelic Therapy Industry
PressSeptember 15, 2022 Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
PressSeptember 15, 2022 Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
PressSeptember 14, 2022 Sunstone Therapies Collaborates with MAPS to Conduct Clinical Trial of MDMA-Assisted Therapy for PTSD
